US equities
|
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
MU
$1,097.39
▲+3.03%
NVDA
$230.86
▲+1.09%
SNDK
$1,787.69
▲+2.75%
INTC
$120.00
▼-0.19%
AAPL
$330.32
▼-0.81%
GOOGL
$338.24
▼-1.70%
TSLA
$354.11
▼-0.20%
AMD
$615.73
▲+0.65%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sage Therapeutics, Inc. - Common Stock
(NQ:
SAGE
)
8.680
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 30, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sage Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Sage (SAGE) Q2 Revenue Jumps 264%
↗
August 01, 2025
Via
The Motley Fool
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
July 31, 2025
Acquisition strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- to...
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Sage Therapeutics Announces Second Quarter 2025 Financial Results
July 30, 2025
From
Sage Therapeutics, Inc.
Via
Business Wire
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
July 28, 2025
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression
July 25, 2025
From
Biogen Inc.
Via
GlobeNewswire
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
July 14, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
↗
July 10, 2025
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Via
Investor's Business Daily
Topics
Intellectual Property
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock
↗
July 08, 2025
Via
Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders
July 05, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 27, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
July 01, 2025
From
FN Media Group LLC
Via
GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, CHTR, SAGE, TASK on Behalf of Shareholders
June 25, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
July 01, 2025
EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
June 23, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
↗
June 22, 2025
Analysts have also noted that the relatively low breakup fee may leave room for a competing offer, possibly from Biogen.
Via
Stocktwits
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
June 18, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
Deep Dive Into Sage Therapeutics Stock: Analyst Perspectives (4 Ratings)
↗
June 17, 2025
Via
Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VERV, SAGE, CTLP, SOAR on Behalf of Shareholders
June 17, 2025
From
Halper Sadeh LLC
Via
GlobeNewswire
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News
↗
June 17, 2025
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - SOAR)
June 17, 2025
From
Brodsky & Smith LLC
Via
GlobeNewswire
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs
↗
June 17, 2025
Via
Benzinga
US Stock Futures Tumble After Trump Threatens 'Real End' To Iran's Nuclear Problem: '...Avoid Getting Whipsawed By Noise,' Says Expert
↗
June 17, 2025
U.S. stock futures were trading lower on Tuesday following Monday's advanced. Futures of major benchmark indices were lower in premarket.
Via
Benzinga
Topics
Government
Dow Surges Over 300 Points As Iran Signals De-Escalation: Investor Sentiment Improves, Fear Index Remains In 'Greed' Zone
↗
June 17, 2025
Via
Benzinga
Topics
Stocks
Monday's session: top gainers and losers
↗
June 16, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June
↗
June 16, 2025
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
↗
June 16, 2025
Via
Benzinga
Top movers in Monday's session
↗
June 16, 2025
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Supernus Pharmaceuticals Gets Retail Excited Over $795M Acquisition Plan For Sage Therapeutics
↗
June 16, 2025
Under the terms of the deal, Supernus is looking to acquire Sage for a total consideration of $12 per share in cash.
Via
Stocktwits
Topics
Government
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday
↗
June 16, 2025
Via
Benzinga
These stocks are gapping in today's session
↗
June 16, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
